M-TEER Benefits in Secondary Mitral Regurgitation: Consistent Clinical and Quality-of-Life Improvements Regardless of Baseline Health Status
Posted inCardiology news

M-TEER Benefits in Secondary Mitral Regurgitation: Consistent Clinical and Quality-of-Life Improvements Regardless of Baseline Health Status

The RESHAPE-HF2 trial reveals that mitral transcatheter edge-to-edge repair (M-TEER) significantly reduces cardiovascular risks and enhances health status across all baseline patient conditions, reinforcing its role as a key intervention for symptomatic heart failure and secondary mitral regurgitation.
Transseptal TMVR with the SAPIEN M3 Lowers 1‑Year Mortality/HF Rehospitalisation in Patients Unsuitable for Surgery or TEER
Posted inCardiology news

Transseptal TMVR with the SAPIEN M3 Lowers 1‑Year Mortality/HF Rehospitalisation in Patients Unsuitable for Surgery or TEER

A multicountry, single‑arm pivotal trial of the SAPIEN M3 transseptal transcatheter mitral valve replacement (TMVR) in patients deemed unsuitable for surgery or TEER demonstrated a 1‑year composite rate of death or heart‑failure rehospitalisation of 25.2%, significantly below the prespecified 45% performance goal, with few intraprocedural complications.
Real-World Insights into Clinical Presentation and Surgical Outcomes of Mitral Regurgitation from the MITRACURE Registry
Posted inCardiology Clinical Updates General Surgery news Specialties

Real-World Insights into Clinical Presentation and Surgical Outcomes of Mitral Regurgitation from the MITRACURE Registry

The MITRACURE international registry reveals that mitral valve surgery patients often present late in disease progression with advanced symptoms, showing modest repair rates and notable in-hospital mortality, underscoring the need for earlier intervention and improved management strategies.